Page 85 - Clinical Development News Today

The French-U.S. company Novadiscovery has hailed a “watershed moment for clinical trial design” as its trial simulation tool successfully predicted the outcome of a phase 3 oncology trial run by AstraZeneca.

SOUTH SAN FRANCISCO, Calif., Sept. 15, 2023 -- Pliant Therapeutics, Inc. , a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of...

Lebrikizumab is an investigational monoclonal antibody that binds to IL-13 protein with high affinity and inhibits its downstream signaling Positive opinion is based on Phase 3 studies which...

The U.S. company Rome Therapeutics plans to use the proceeds of its $72 million Series B round to take an experimental autoimmune disease treatment through early clinical testing.

PV&ME™ campaign features personal stories from people living with PV and their journeys navigating the rare blood cancerBURLINGTON, Mass. & EAST LANSING, Mich.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwa...

/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and...

/PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company developing novel metallotherapeutics, is announcing its selection by Life...

A partnership deal between the Dutch digital health company Congenica and clinical trial platform provider myTomorrows will see the companies pooling their technologies to help more patients receive precision oncology treatments.

- Final European Commission decision expected within 67 days after positive opinion; if approved, first European Union launch planned in Germany in early 2024 COPENHAGEN, Denmark, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion and recommended the approval of TransCon PTH (palopegteriparatide) as a parathyroid hormone (PTH) replace...

Insilico Medicine is due to receive $80 million upfront plus potential milestone payments as Exelixis gains global rights to develop and commercialize the Hong Kong firm’s small molecule cancer treatment.